These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 2625114)

  • 1. [Intrapleural transfer of LAK cells combined with rIL-2 in the treatment of advanced lung cancer with malignant pleural effusion].
    Li DJ
    Zhonghua Zhong Liu Za Zhi; 1989 Jul; 11(4):294-6. PubMed ID: 2625114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effectiveness of treatment with transfer of autologous or allogenic LAK cells combined with rIL-2 in 121 patients with malignant pleural effusion].
    Liu X
    Zhonghua Zhong Liu Za Zhi; 1993 May; 15(3):205-8. PubMed ID: 8261867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intrapleural administration of LAK cells combined with rIL2 in the treatment of advanced lung cancer with malignant pleural effusion].
    Mao G; Gao Z; Wang Q
    Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):83-4, 127. PubMed ID: 7553956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of patients with malignant pleural effusions due to advanced lung cancer by transfer of autologous LAK cells combined with rIL-2 or rIL-2 alone.
    Li D; Wang Y; Yao X; Shao J; Chen Y; Ba D
    Proc Chin Acad Med Sci Peking Union Med Coll; 1990; 5(1):51-5. PubMed ID: 2371266
    [No Abstract]   [Full Text] [Related]  

  • 5. A new approach to the treatment of malignant effusion.
    Li DJ; Wang YR; Tan XY; Wang HZ; Yao XD; Ba DN
    Chin Med J (Engl); 1990 Dec; 103(12):998-1002. PubMed ID: 2127253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer.
    Yasumoto K; Mivazaki K; Nagashima A; Ishida T; Kuda T; Yano T; Sugimachi K; Nomoto K
    Cancer Res; 1987 Apr; 47(8):2184-7. PubMed ID: 3493843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of 121 patients with malignant effusion due to advanced lung cancer by intrapleural transfer of autologous or allogeneic LAK cells combined with rIL-2.
    Liu X; Li D; Zhang C; Ba D; Liu J; Wan T; Li Z; Jin Y; He Y
    Chin Med Sci J; 1993 Sep; 8(3):186-9. PubMed ID: 8142637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Experimental and clinical studies on intrapleural instillations of interleukin-2 (IL-2) in patients with malignant pleural effusion].
    Suzuki H
    Nihon Geka Gakkai Zasshi; 1989 Nov; 90(11):1922-31. PubMed ID: 2608022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
    Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
    Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adoptive immunotherapy of cancer patients with lymphokine-activated killer cells].
    Taguchi T; Domoto K
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):914-21. PubMed ID: 3494428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study of the cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells.
    Guo YS; Xing ZL
    Chin Med J (Engl); 1994 Dec; 107(12):903-5. PubMed ID: 7882727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells].
    Guo Y; Xing Z
    Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):80-2, 127. PubMed ID: 7553955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The intrapleural administration of recombinant interleukin-2 (rIL-2) to patients with malignant pleural effusion: clinical trials.
    Suzuki H; Abo S; Kitamura M; Hashimoto M; Izumi K
    Surg Today; 1993; 23(12):1053-9. PubMed ID: 8118118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adoptive immunotherapy of malignant pleural effusion with TIL/rIL2 (tumor-infiltrating lymphocytes/recombinant interleukin 2)].
    Han B; Jia Y; Zhou M
    Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):91-3, 128. PubMed ID: 7553959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
    Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ
    Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Induction by local injections of IL-2 of antitumor effector cells and secondary production of cytokines in malignant pleural effusion].
    Sone S; Yanagawa H; Nii A; Ozaki T; Ogura T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Aug; 30(8):1434-40. PubMed ID: 1434216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
    Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
    Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.